What Is in Apoquel for Dogs? Ingredients Explained

Apoquel contains one active ingredient: oclacitinib maleate, a synthetic compound designed to block specific immune-signaling pathways that trigger itching and inflammation in dogs. The rest of the tablet is made up of standard pharmaceutical fillers, binders, and coatings that hold the pill together and help it dissolve properly. While the inactive ingredients are unremarkable, the active molecule itself is worth understanding because it explains both why Apoquel works so quickly and why veterinarians treat it with a degree of caution.

Oclacitinib Maleate, the Active Molecule

The drug doing the work in every Apoquel tablet is oclacitinib maleate. “Oclacitinib” is the drug itself, and “maleate” refers to the salt form used to stabilize it in tablet form, a common pharmaceutical technique that makes a compound easier to manufacture and absorb. Oclacitinib belongs to a class of drugs called Janus kinase inhibitors, which were originally developed for human medicine and then adapted for veterinary use. The U.S. Food and Drug Administration approved Apoquel in 2013 specifically for dogs, making it the first JAK inhibitor licensed for veterinary dermatology.¹

Apoquel is approved for dogs at least 12 months of age to control itching associated with allergic dermatitis and to manage atopic dermatitis, a chronic allergic skin condition. It comes in film-coated tablets in three strengths: 3.6 mg, 5.4 mg, and 16 mg. The dose your vet prescribes depends on your dog’s body weight, typically around 0.4 to 0.6 mg per kilogram given twice daily for the first two weeks, then once daily for maintenance.

How Oclacitinib Targets Itching and Inflammation

To understand what oclacitinib actually does once your dog swallows it, it helps to know a bit about what causes allergic itching in the first place. When a dog with allergies encounters a trigger, whether that is pollen, dust mites, or flea saliva, its immune system releases signaling molecules called cytokines. Several of these cytokines, especially one called IL-31, directly stimulate itch-sensing nerves in the skin. Others, like IL-4 and IL-13, drive the redness, swelling, and skin-barrier breakdown that make allergic dermatitis so miserable for affected dogs.

These cytokines depend on enzymes called Janus kinases (JAKs) to relay their signals inside cells. Oclacitinib works by physically blocking JAK enzymes, preventing the cytokine signals from going through. It is most potent against the JAK1 enzyme, with roughly ten times more selectivity for JAK1 compared to JAK3 and nearly twice the selectivity for JAK1 over JAK2. In lab testing, oclacitinib did not meaningfully inhibit 38 other kinases, which is why it is described as a targeted therapy rather than a broad immune suppressant.²

The practical result is that oclacitinib shuts down the specific cytokines most responsible for allergic itch and skin inflammation, including IL-2, IL-4, IL-6, IL-13, and IL-31, while largely leaving other immune functions alone. It is much less effective at blocking erythropoietin and GM-CSF, two signaling molecules involved in red blood cell production and broader immune defense, which is part of why the drug’s side-effect profile is narrower than older treatments like steroids.²

Inactive Ingredients and Tablet Design

Beyond the active molecule, the rest of an Apoquel tablet consists of inactive ingredients typical of film-coated oral tablets. These include fillers like lactose monohydrate and microcrystalline cellulose that give the tablet its bulk, a disintegrant like sodium starch glycolate that helps it break apart in the stomach, magnesium stearate as a lubricant to keep the tablet from sticking to manufacturing equipment, and a thin film coating made from ingredients like polyvinyl alcohol and titanium dioxide. None of these inactive components have any therapeutic effect. They exist to make the tablet structurally sound, easy to swallow, and shelf-stable.

If your dog is one of many that refuses to take pills, a flavored chewable version of Apoquel has also been developed. In clinical testing, more than 90% of dogs freely accepted the chewable when offered, a substantial improvement over trying to hide a film-coated tablet in cheese or peanut butter.³ The chewable contains the same active ingredient at the same dose, plus flavoring agents and a different binder matrix to create its soft, palatable texture. The active molecule and its effects are identical between the two forms.

Speed of Action

One of the reasons Apoquel became popular so quickly after its approval is how fast it works. In a controlled study using dogs whose itching was experimentally triggered, oclacitinib reduced scratching by about 61% within just an hour and a half of a single oral dose, with an average reduction of 85% over the first one-to-five-hour window after dosing.⁴ In a larger clinical trial with dogs suffering from real-world allergic dermatitis, the drug produced a meaningful drop in itch scores within 24 hours. Over the course of treatment, average itch scores fell from a high of roughly 7.6 out of 10 to about 2.6, a dramatic improvement that was consistently better than placebo at every assessment point.⁵

The chewable formulation performs comparably. Both the film-coated tablet and the chewable significantly reduced experimentally induced itching within one to three hours, with no meaningful difference in speed between the two forms.³ This quick onset is a direct consequence of oclacitinib’s pharmacokinetics. The drug absorbs rapidly after oral dosing, reaches peak blood levels quickly, and begins blocking JAK1 signaling within a short window.

Known Side Effects and What They Reflect About the Ingredients

Because oclacitinib modulates the immune system, even in a relatively targeted way, it carries a side-effect profile that dog owners should be aware of. In a long-term study tracking dogs on oclacitinib for extended periods, the most commonly reported issues, occurring in more than 5% of treated dogs, included urinary tract infections or cystitis, vomiting, ear infections (otitis), skin infections (pyoderma), and diarrhea.⁶

The vomiting and diarrhea are gastrointestinal effects that can accompany many oral medications and are not unique to oclacitinib. The infections are more telling. By dampening certain immune-signaling pathways, oclacitinib can make dogs slightly more susceptible to bacterial infections of the skin and urinary tract. A critical appraisal of the published literature also flagged broader immunomodulatory concerns, including increased susceptibility to infections and a potential association with neoplasms (tumors) during long-term use.⁷ This does not mean Apoquel causes cancer, but the relationship between long-term immune modulation and tumor surveillance is something veterinary dermatologists keep an eye on, and it is one reason your vet may recommend periodic blood work or check-ups for dogs on the medication long-term.

None of the inactive ingredients in either the tablet or chewable formulation are known to cause significant adverse effects in dogs. Lactose intolerance is far less common in dogs than in adult humans, and the tiny amounts of lactose in a tablet filler are unlikely to cause digestive upset. If your dog does experience vomiting after taking Apoquel, the active ingredient is the more likely culprit, not the binders or coatings.

How Apoquel Compares to Steroids

Before Apoquel arrived, the standard treatment for allergic itch in dogs was corticosteroids, most commonly prednisolone or prednisone. These drugs are cheap and effective, but they work by suppressing a much wider swath of the immune system, leading to a long list of side effects with chronic use: increased thirst and urination, weight gain, muscle wasting, thinning skin, and increased vulnerability to infections and metabolic disorders like diabetes.

In a head-to-head clinical trial, oclacitinib reduced itching and skin lesions to a level comparable to prednisolone given at standard doses.⁸ The appeal of oclacitinib is not that it works better than steroids for itch relief but that it achieves similar results while targeting a narrower part of the immune system. Over the long term, dogs on oclacitinib tend to avoid the metabolic fallout that makes chronic steroid use so problematic. That said, oclacitinib is substantially more expensive than prednisolone, which is a generic drug that costs pennies per dose. For some dog owners, cost is a real factor in the treatment decision.

Another alternative your vet may mention is lokivetmab, marketed as Cytopoint, which is a monoclonal antibody injection that specifically neutralizes IL-31. Because it is a biologic rather than a small molecule, it works differently from oclacitinib and does not interact with the JAK pathway at all. Some dogs respond better to one or the other, and the two are sometimes used together for dogs with severe atopic dermatitis that does not respond well to a single agent.

Why Apoquel Is Restricted to Dogs Over 12 Months

The FDA approval for Apoquel specifies dogs at least 12 months of age.¹ This restriction exists because younger dogs have immune systems that are still developing. The cytokines that oclacitinib blocks, particularly IL-2, play roles in normal immune maturation and the establishment of long-term immune memory. Suppressing those signals in a puppy whose immune system has not yet fully formed could interfere with normal development and potentially leave the dog more vulnerable to infections during a critical window. The safety data that supported FDA approval was generated in adult dogs, so there simply is not enough evidence to confirm the drug is safe in puppies. Vets may occasionally prescribe it off-label for younger dogs with severe allergic disease when other options have failed, but this is a case-by-case judgment call rather than standard practice.

What the Ingredients Do Not Do

A common misconception about Apoquel is that it treats the underlying cause of allergies. It does not. Oclacitinib controls symptoms by blocking the signaling cascade that produces itching and inflammation. The moment you stop giving the drug, those signals resume, and the itching typically returns. Apoquel is a management tool, not a cure. For dogs with atopic dermatitis, the underlying immune dysfunction that makes them allergically reactive to environmental triggers remains. Allergen-specific immunotherapy, sometimes called “allergy shots,” is the only treatment that attempts to change the immune response itself, though it works slowly and not in every dog.

It is also worth knowing that oclacitinib is not an antihistamine, even though it is sometimes casually lumped into the same category as allergy medications. Antihistamines like diphenhydramine (Benadryl) block histamine receptors, which is a completely different mechanism. Histamine plays a relatively minor role in canine allergic itch compared to cytokines like IL-31, which is why antihistamines rarely work well for dogs with atopic dermatitis and why a drug that blocks the JAK1 pathway tends to be far more effective.

Giving Apoquel Safely

The standard dosing protocol is twice daily for the first 14 days, then once daily for ongoing maintenance. This front-loading schedule allows the drug to build up and get the itching under control before stepping down to a dose that maintains relief without excessive immune suppression. Skipping the step-down to once daily is not recommended, because prolonged twice-daily dosing increases the cumulative immune effect and the likelihood of side effects like infections.

Apoquel can be given with or without food. If your dog tends to vomit on an empty stomach, giving it with a small meal may help. There are no known food interactions that change how the drug is absorbed or metabolized. For dogs that are also on other medications, oclacitinib has shown a relatively clean interaction profile, though you should always tell your vet about everything your dog takes, including supplements. The drug is primarily metabolized in the liver, so dogs with significant liver disease may process it differently, and your vet may want to monitor liver values periodically.

One practical note about the tablet strengths: the three sizes (3.6 mg, 5.4 mg, and 16 mg) are designed so that most dogs can be dosed with whole tablets or simple combinations. Splitting Apoquel tablets is generally discouraged because the film coating is part of what controls how the drug dissolves, and a broken tablet may not deliver the dose as intended. If your dog falls between weight categories, your vet will tell you which tablet combination to use.

Dogs That Should Not Take Apoquel

Beyond the age restriction, there are several situations where oclacitinib is not appropriate. Dogs with serious pre-existing infections should not start the drug until the infection is treated, because dampening immune signaling could make it harder for the body to fight off the existing illness. Dogs with a history of certain cancers may also be poor candidates, given the theoretical concern about reduced immune surveillance against abnormal cells during long-term use.

Breeding dogs, pregnant dogs, and nursing dogs fall into a gray area. There is limited safety data for oclacitinib in these populations, and most veterinary dermatologists recommend avoiding it during pregnancy and lactation unless the benefit clearly outweighs the risk. Dogs with demodicosis, a skin condition caused by Demodex mites that proliferate when the immune system is suppressed, should also be treated with caution, since oclacitinib’s immune-modulating effects could theoretically worsen the mite overgrowth.

If your dog has been taking Apoquel and develops new lumps, persistent infections, or unusual lethargy, these are reasons to check in with your vet. The drug is considered safe for most dogs when used as directed, but “safe” in pharmacology always means that the benefits outweigh the risks for the intended population, not that the risks are zero. Regular veterinary follow-up is part of responsible long-term use, particularly for dogs on the medication for months or years at a stretch.